Mobile

A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study to Investigate the Safety and Tolerability of YM150 in Subjects with Non-Valvular Atrial Fibrillation and to Compar...

Update Il y a 4 ans
Reference: EUCTR2007-001150-87

A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study to Investigate the Safety and Tolerability of YM150 in Subjects with Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability with Warfarin

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective is to investigate the optimal daily dose and dose regimen of YM150 in subjects with NVAF, primarily based on safety and tolerability data.

Inclusion criteria

  • the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF)

Links